| Identification | Back Directory | [Name]
SP-420 | [CAS]
911714-45-9 | [Synonyms]
SP-420
CS-2097
SP420;SP 420
(4S)-4,5-Dihydro-2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid
4-Thiazolecarboxylic acid, 4,5-dihydro-2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-, (4S)-
(2E,4S)-2-[4-[2-(2-methoxyethoxy)ethoxy]-6-oxocyclohexa-2,4-dien-1-ylidene]-4-methyl-1,3-thiazolidine-4-carboxylic acid | [Molecular Formula]
C16H21NO6S | [MOL File]
911714-45-9.mol | [Molecular Weight]
355.41 |
| Chemical Properties | Back Directory | [Melting point ]
82-83℃ (ethyl acetate hexane ) | [Boiling point ]
562.2±60.0 °C(Predicted) | [density ]
1.32±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10mg/mL; DMSO: 15mg/mL; Ethanol: 15mg/mL; Ethanol:PBS (pH 7.2) (1:4): 0.2mg/mL | [form ]
A crystalline solid | [pka]
1.02±0.40(Predicted) | [color ]
Light yellow to khaki |
| Hazard Information | Back Directory | [Description]
SP 420 is an iron chelator and a derivative of desferrothiocin. It induces iron excretion in rat bile and urine with an iron-clearing efficiency (ICE) value of 26.7% when administered at a dose of 300 μmol/kg and decreases iron levels in rat liver and heart at 384 μmol/kg per day. SP 420 (75 μmol/kg) also induces iron excretion in iron-overloaded C. apella monkeys (ICE = 26.3%). | [Uses]
Petadeferitrin is a tridentate iron chelator belonging to the class of iron chelators, with oral activity. Petadeferitrin can be used in research related to β-thalassemia[1][2][3]. | [in vivo]
Petadeferitrin causes renal function abnormalities, including increased serum creatinine, proteinuria, increased urine protein/creatinine ratio, and glycosuria[3]. | [References]
[1] Bergeron RJ, et al. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles. J Med Chem. 2012 Aug 23;55(16):7090-103. DOI:10.1021/jm300509y
[2] Basu S, et al. Understanding the intricacies of iron overload associated with β-thalassemia: a comprehensive review[J]. Thalassemia Reports, 2023, 13(3): 179-194.
[3] Taher A T, et al. Safety and pharmacokinetics of the oral iron chelator SP‐420 in β‐thalassemia[J]. American Journal of Hematology, 2017, 92(12): 1356-1361. DOI:10.1002/ajh.24914 |
|
|